Immunocore Holdings plc

IMCR

US45258D1054

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 11:21:05 23/05/2024 pm IST			5-day change	1st Jan Change
48.55 ^USD	-3.80%		-9.94%	-28.49%

13/05	Mizuho Cuts Price Target on Immunocore to $88 From $90, Keeps Buy Rating	MT
08/05	Immunocore Holdings' Shares Fall After Q1 Net Loss Widens	MT

Immunocore Limited Names David Berman as Head of R&D

January 15, 2019 at 12:30 pm IST

Immunocore Limited names David Berman as its new Head of Research and Development. David joined the company in September 2018 to advance the company’s lead candidate, IMCgp100, towards commercialization and progress the company’s growing pipeline of TCR candidates through clinical development.

Latest news about Immunocore Holdings plc

Mizuho Cuts Price Target on Immunocore to $88 From $90, Keeps Buy Rating	13/05	MT
Immunocore Holdings' Shares Fall After Q1 Net Loss Widens	08/05	MT
Earnings Flash (IMCR) IMMUNOCORE HOLDINGS Reports Q1 Revenue $70.5M	08/05	MT
Immunocore Holdings plc Reports Earnings Results for the First Quarter Ended March 31, 2024	08/05	CI
Leerink Partners Starts Immunocore Holdings With Outperform Rating, $74 Price Target	29/04	MT
Immunocore Holdings Files Mixed-Securities Shelf Registration	21/03	MT
Transcript : Immunocore Holdings plc Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-14-2024 09:30 AM	14/03
Mizuho Securities Raises Immunocore Price Target to $90 From $86, Maintains Buy Rating	05/03	MT
Oppenheimer Adjusts Immunocore Price Target to $87 From $85, Maintains Outperform Rating	29/02	MT
Immunocore Holdings' Q4 Net Loss Narrows, Revenue Rises	28/02	MT
Transcript : Immunocore Holdings plc, Q4 2023 Earnings Call, Feb 28, 2024	28/02
Earnings Flash (IMCR) IMMUNOCORE HOLDINGS LIMITED Reports Q4 Revenue $70.2M, vs. Street Est of $68.5M	28/02	MT
Immunocore Holdings plc Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	28/02	CI
Immunocore Holdings plc Reports Earnings Results for the Full Year Ended December 31, 2023	28/02	CI
Immunocore Collaborates With Bristol Myers Squibb in Advanced Cutaneous Melanoma Trial	22/02	MT
Mizuho Raises Price Target on Immunocore to $86 From $72 Ahead of Q4 2023 Earnings Announcement, Reiterates Buy Rating	15/02	MT
Immunocore Prices Upsized $350 Million Convertible Notes Offering	31/01	MT
Sector Update: Health Care Stocks Lean Lower Premarket Tuesday	30/01	MT
Immunocore Plans $300 Million Convertible Senior Notes Offering ; Shares Fall After-Hours	30/01	MT
Immunocore Holdings plc Provides Preliminary Unaudited Revenue Guidance for the Fourth Quarter and Full Year 2023	30/01	CI
Transcript : Immunocore Holdings plc Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-10-2024 09:00 AM	10/01
Immunocore Holdings Insider Sold Shares Worth $305,781, According to a Recent SEC Filing	06/01	MT
Immunocore Plans to Boost Sales, Expand Access to Kimmtrak in 2024	05/01	MT
Immunocore Holdings plc Announces the Addition of Two New Pre-Clinical Candidates for Autoimmune Diseases to Its Pipeline	05/01	CI
Mizuho Cuts Price Target on Immunocore to $72 From $74, Reiterates Buy Rating	10/11	MT

Chart Immunocore Holdings plc

Duration

Period

More charts

Company Profile

Immunocore Holdings plc is a United Kingdom-based commercial-stage biotechnology company. The Company is engaged in the development of TCR bispecific immunotherapies, ImmTAX, which immunes mobilizing monoclonal TCRs Against X disease, designed to treat a range of diseases, including cancer, autoimmune and infectious disease. The Company has a clinical-stage pipeline of wholly owned and partnered programs across three different therapeutic areas: oncology, infectious diseases, and autoimmune and inflammation diseases. Its lead product, KIMMTRAK, is a TCR therapeutic for the treatment of patients with unresectable or metastatic uveal melanoma (mUM), in the United States, European Union, Canada, Australia and the United Kingdom. Its pipeline products include IMC-F106C, IMC-F115C, IMC-F119C, IMC-F117C, IMC-F113V, IMC-I109V, IMC-SII8AI, among others. Its clinical programs are being conducted with patients with a range of cancers including melanoma, lung, gastric and others.

Sector

Pharmaceuticals

Calendar

31/05/2024 - American Society of Clinical Oncology Annual Meeting - Omid Hamid

More about the company

Income Statement Evolution

More financial data

Ratings for Immunocore Holdings plc

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

39.66 GBP

Average target price

67.7 GBP

Spread / Average Target

+70.71%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
IMMUNOCORE HOLDINGS PLC	-28.49%	252.41Cr
ELI LILLY AND COMPANY	+39.64%	72TCr
NOVO NORDISK A/S	+34.28%	59TCr
JOHNSON & JOHNSON	-4.20%	37TCr
MERCK & CO., INC.	+20.27%	33TCr
ABBVIE INC.	+2.72%	28TCr
ASTRAZENECA PLC	+17.02%	24TCr
NOVARTIS AG	+9.31%	21TCr
ROCHE HOLDING AG	-5.07%	21TCr
PFIZER, INC.	-0.02%	17TCr

Other Pharmaceuticals

Immunocore Holdings plc

Equities

IMCR

US45258D1054

Pharmaceuticals

Immunocore Limited Names David Berman as Head of R&D

EPS Revisions